5:34 PM
 | 
May 23, 2013
 |  BC Extra  |  Clinical News

Merck discontinues preladenant for PD

Merck & Co. Inc. (NYSE:MRK) said it no longer plans to submit regulatory applications for preladenant to treat Parkinson's disease after an initial...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >